Compare Abbott Laboratories (ABT) vs NetEase Inc (NTES) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs NetEase Inc — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while NetEase Inc trades at $133.8 (market cap $83.83B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | NTES | |
|---|---|---|
Market Cap | $166.94B | $83.83B |
Sector | Health | Media |
52-Week High | $136.62 | $159.34 |
52-Week Low | $82.57 | $109.26 |
Enterprise Value | $193.69B | $60.31B |
Dividend Yield | 2.63% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
NetEase (NTES) trades at $130.82, up 2.81% today, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings that beat estimates, with revenue growth to $112.63B in 2025 and a net income margin of 29.84%. Recent news highlights international expansion and a $0.72 dividend payment scheduled for June 2026.
The stock presents a compelling value with a P/E of 16.83 and robust profitability metrics. Analyst consensus is strongly bullish with 82% buy ratings and a 34.7% upside potential. Key risks include reliance on the Chinese market and competitive pressures in gaming. Cash flow trends show volatility, but the balance sheet remains strong with $137.58B in cash.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
